Inhibrx, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own31.57% Shs Outstand39.02M Perf Week-1.19%
Market Cap443.05M Forward P/E- EPS next Y-3.52 Insider Trans-0.00% Shs Float26.71M Perf Month3.21%
Income-93.70M PEG- EPS next Q-0.82 Inst Own65.40% Short Float12.83% Perf Quarter-48.03%
Sales7.30M P/S60.69 EPS this Y-6.60% Inst Trans8.15% Short Ratio7.66 Perf Half Y-73.11%
Book/sh0.70 P/B16.54 EPS next Y-12.70% ROA-64.30% Target Price47.00 Perf Year-62.52%
Cash/sh3.75 P/C3.09 EPS next 5Y- ROE-246.30% 52W Range7.67 - 47.90 Perf YTD-73.48%
Dividend- P/FCF- EPS past 5Y- ROI-62.30% 52W High-75.82% Beta-
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low50.98% ATR1.13
Employees106 Current Ratio7.50 Sales Q/Q0.00% Oper. Margin- RSI (14)49.65 Volatility9.25% 11.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-56.70% Profit Margin- Rel Volume0.54 Prev Close11.35
ShortableYes LT Debt/Eq3.98 Earnings- Payout- Avg Volume447.67K Price11.58
Recom1.80 SMA208.94% SMA50-12.09% SMA200-57.79% Volume243,190 Change2.03%
Mar-16-22Initiated SMBC Nikko Outperform $40
Sep-21-21Initiated JMP Securities Mkt Outperform $46
Apr-26-21Resumed Credit Suisse Outperform $44
Sep-14-20Initiated Evercore ISI Outperform $30
Sep-14-20Initiated Credit Suisse Outperform $26
Jun-30-22 09:00AM  
May-19-22 04:05PM  
May-16-22 12:32PM  
May-09-22 06:35PM  
May-05-22 05:15PM  
May-03-22 06:32AM  
Apr-25-22 09:00AM  
Apr-05-22 04:30PM  
Mar-24-22 04:05PM  
Mar-03-22 09:15AM  
Feb-28-22 04:05PM  
Feb-22-22 09:00AM  
Jan-05-22 07:46AM  
Jan-04-22 04:05PM  
Dec-20-21 08:50AM  
Dec-01-21 04:05PM  
Nov-25-21 09:08AM  
Nov-24-21 10:31AM  
Nov-23-21 10:00AM  
Nov-10-21 07:47AM  
Nov-09-21 06:45PM  
Nov-05-21 03:00PM  
Nov-03-21 08:00AM  
Nov-01-21 05:51PM  
Oct-28-21 08:30AM  
Oct-12-21 12:22PM  
Oct-11-21 04:05PM  
Sep-13-21 04:30PM  
Aug-12-21 01:37AM  
Aug-09-21 04:38PM  
Jun-22-21 06:49AM  
Jun-21-21 04:05PM  
May-17-21 04:05PM  
May-13-21 04:10PM  
Mar-14-21 03:21AM  
Mar-12-21 09:00AM  
Feb-01-21 05:42PM  
Jan-13-21 09:00AM  
Dec-10-20 06:24PM  
Nov-13-20 04:10PM  
Nov-11-20 04:05PM  
Nov-05-20 04:05PM  
Aug-25-20 12:17PM  
Aug-21-20 04:00PM  
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eckelman Brendan P.Chief Scientific OfficerApr 05Sale25.0440010,0162,555,553Apr 07 04:11 PM